Fresenius Medical Care (SWX:FME) - Cotización, noticias y análisis

Resumen de acción FME

Fresenius Medical Care AG ofrece diálisis y servicios relacionados para personas con enfermedades renales en Alemania, Norteamérica e internacionalmente.

Acerca de la empresa

FME fundamental analysis
Snowflake Score
Valuation	4/6
Future Growth	3/6
Past Performance	1/6
Financial Health	4/6
Dividends	5/6

Recompensas

Cotiza un 61.9% por debajo de nuestra estimación de su valor razonable

Se prevé un crecimiento anual de los beneficios de 27.92%

Paga dividendo fiable de 2.94%

Análisis de riesgos

Tiene un alto nivel de endeudamiento

Competidores de Fresenius Medical Care AG

Galenica

SWX:GALE

CHF3.5b

Sonova Holding

SWX:SOON

CHF14.8b

Ypsomed Holding

SWX:YPSN

CHF5.2b

Straumann Holding

SWX:STMN

CHF21.2b

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for Fresenius Medical Care
Historical stock prices
Current Share Price	€81.20
52 Week High	€0
52 Week Low	€0
Beta	0.93
1 Month Change	0%
3 Month Change	0%
1 Year Change	0%
3 Year Change	0%
5 Year Change	-2.54%
Change since IPO	1.75%

Noticias y actualizaciones recientes

Recent updates

Rentabilidad de los accionistas

	FME	CH Healthcare	Mercado CH
7D	0%	1.8%	-0.9%
1Y	0%	-8.0%	-4.0%

Rentabilidad vs. Industria: FME superó al sector Swiss Healthcare , que obtuvo un rendimiento del -1.1% el año pasado.

Rentabilidad vs. Mercado: FME superó al mercado Swiss, que obtuvo un rendimiento del -1.2% el año pasado.

Volatilidad de los precios

Is FME's price volatile compared to industry and market?
FME volatility
FME Average Weekly Movement	0%
Healthcare Industry Average Movement	4.7%
Market Average Movement	3.5%
10% most volatile stocks in CH Market	7.4%
10% least volatile stocks in CH Market	1.9%

Precio estable de las acciones: FME no ha tenido una volatilidad de precios significativa en los últimos 3 meses.

Volatilidad a lo largo del tiempo: Datos insuficientes para determinar el cambio de volatilidad de FME en el último año.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
1996	119,845	Helen Giza	www.freseniusmedicalcare.com

Fresenius Medical Care AG proporciona diálisis y servicios relacionados para personas con enfermedades renales en Alemania, Norteamérica e internacionalmente. La empresa ofrece tratamiento de diálisis y servicios relacionados de laboratorio y diagnóstico a través de una red de clínicas de diálisis ambulatorias; materiales, formación y servicios de apoyo al paciente que comprenden la supervisión clínica, la asistencia de seguimiento y la organización de la entrega de los suministros en el domicilio del paciente; y servicios de diálisis bajo contrato con hospitales de Estados Unidos para los pacientes hospitalizados con enfermedad renal en fase terminal (ESRD) y para pacientes que sufren insuficiencia renal aguda. También desarrolla, fabrica y distribuye diversos productos sanitarios, como dializadores de polisulfona, máquinas de hemodiálisis, cicladoras de diálisis peritoneal, soluciones de diálisis peritoneal, concentrados, soluciones y granulados de hemodiálisis, líneas sanguíneas, productos farmacéuticos renales, sistemas para el tratamiento del agua y productos cardiopulmonares agudos y de aféresis.

Resumen de fundamentos de Fresenius Medical Care AG

¿Cómo se comparan los beneficios e ingresos de Fresenius Medical Care con su capitalización de mercado?
Estadísticas fundamentales de FME
Capitalización bursátil	CHF10.43b
Beneficios(TTM)	CHF484.52m
Ingresos (TTM)	CHF18.89b

21.5x

Ratio precio-beneficio (PE)

0.6x

Ratio precio-ventas (PS)

¿Está FME sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de FME
Ingresos	€19.45b
Coste de los ingresos	€14.53b
Beneficio bruto	€4.93b
Otros gastos	€4.43b
Beneficios	€499.00m

Últimos beneficios comunicados

Dec 31, 2023

Próxima fecha de beneficios

May 07, 2024

Beneficios por acción (BPA)	1.70
Margen bruto	25.32%
Margen de beneficio neto	2.57%
Ratio deuda/patrimonio	53.3%

¿Cómo se ha desempeñado FME a largo plazo?

Ver rendimiento histórico y comparativa

Dividendos

3.2%

Rentabilidad actual por dividendo

70%

Ratio de pagos

¿Paga FME dividendos fiables?

Ver historial de dividendos e índices de referencia de FME

¿Cuándo hay que comprar FME para recibir un próximo dividendo?
fechas de dividendos de Fresenius Medical Care
Fecha ex dividendo	May 17 2024
Fecha de pago de dividendos	May 22 2024
Días hasta ex dividendo	24 days
Días hasta la fecha de pago de dividendos	29 days

¿Paga FME dividendos fiables?

Ver historial de dividendos e índices de referencia de FME

Resumen de acción FME

Recompensas

Análisis de riesgos

Competidores de Fresenius Medical Care AG

SWX:GALE

CHF3.5b

SWX:SOON

CHF14.8b

SWX:YPSN

CHF5.2b

SWX:STMN

CHF21.2b

Historial de precios y rendimiento

Noticias y actualizaciones recientes

Fresenius Medical Care Launches Augmented Reality for Training on Kidney Replacement Therapy Device

Fresenius Medical Care AG Appoints Jörg Häring as New Global Head of Legal, Compliance and Human Resources and Also Assume the Role of Labor Director, Effective from June 1, 2024

Dividend of €1.19 announced

Fresenius Medical Care AG Proposes Dividend for the Fiscal Year 2023

Fresenius Medical Care AG Provides Earnings Guidance for Fiscal Year 2024

Fresenius Medical Care Brings Dialysis Therapy to Kidney Disease Patients in the U.S

Recent updates

Fresenius Medical Care Launches Augmented Reality for Training on Kidney Replacement Therapy Device

Fresenius Medical Care AG Appoints Jörg Häring as New Global Head of Legal, Compliance and Human Resources and Also Assume the Role of Labor Director, Effective from June 1, 2024

Dividend of €1.19 announced

Fresenius Medical Care AG Proposes Dividend for the Fiscal Year 2023

Fresenius Medical Care AG Provides Earnings Guidance for Fiscal Year 2024

Fresenius Medical Care Brings Dialysis Therapy to Kidney Disease Patients in the U.S

Fresenius Medical Care Enters into Favorable Settlement Agreement with U. S. Government

Fresenius Medical Care AG & Co. Revises Earnings Guidance for the Year 2023

New minor risk - Earnings quality

Fresenius Medical Care AG & Co. KGaA to Report Fiscal Year 2023 Final Results on Mar 22, 2024

An Unknown buyer entered into an agreement to acquire National Cardiovascular Partners, LP from Fresenius Medical Care AG & Co. KGaA (XTRA:FME)

Third quarter 2023 earnings released: EPS: €0.29 (vs €0.78 in 3Q 2022)

Fresenius Medical Care AG & Co. KGaA to Report Q1, 2024 Results on May 07, 2024

Fresenius Medical Care Appoints Craig Cordola as New Management Board Member for Care Delivery

Fresenius Medical Care Achieves Key Ai Milestone with First-Phase Completion of Largest Global Dialysis Clinical Dataset

Fresenius Medical Care Announces Fda Clearance of Versi(R)Hd with Guideme Software

New minor risk - Financial position

Second quarter 2023 earnings released: EPS: €0.48 (vs €0.50 in 2Q 2022)

An unknown buyer acquired Local dialysis service provider business from Fresenius Medical Care AG & Co. KGaA (XTRA:FME).

Fresenius Medical Care Announces Executive Changes

Fresenius Medical Care participated Announces Breakthrough Study Demonstrates That High-Dose Hemodiafiltration Treatment for Kidney Failure Patients Significantly Reduces Mortality Rates

Upcoming dividend of €1.12 per share at 2.5% yield

Full year 2022 earnings released: EPS: €2.30 (vs €3.31 in FY 2021)

Fresenius Medical Care AG & Co. KGaA Announces CEO Changes

Fresenius Medical Care AG & Co. KGaA, Annual General Meeting, May 16, 2023

Fresenius Medical Care AG & Co. KGaA to Report Q2, 2023 Results on Aug 02, 2023

Third quarter 2022 earnings released: EPS: €0.78 (vs €0.93 in 3Q 2021)

Second quarter 2022 earnings released: EPS: €0.50 (vs €0.75 in 2Q 2021)

Fresenius Medical Care AG & Co. KGaA Revises Earnings Guidance for the Full Year 2022

Fresenius Medical Care AG & Co. KGaA Provides Earnings Guidance for the Second Half of 2022

Fresenius Medical Care AG & Co. KGaA to Report Q3, 2022 Final Results on Nov 09, 2022

First quarter 2022 earnings released: EPS: €0.54 (vs €0.85 in 1Q 2021)

Upcoming dividend of €1.35 per share

Fresenius Medical Care Appoints Nwamaka (Amaka) Eneanya as Head of Strategy and Operations for the Company's Global Medical Office

Fresenius Medical Care AG & Co. KGaA Proposes Dividend, Due on 17 May 2022

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Fresenius Medical Care Ag & Co. Kgaa Provides Earnings Forecast for the Year 2022

Fresenius Medical Care Reportedly in Talks to Buy Dmed Diyaliz

Fresenius Medical Care AG & Co. KGaA Launches New Mobile App to Empower and Engage Nurses

Third quarter 2021 earnings released: EPS €0.93 (vs €1.21 in 3Q 2020)

Second quarter 2021 earnings released: EPS €0.75 (vs €1.20 in 2Q 2020)

Independent Member of Supervisory Board has left the company

Fresenius Medical Care Approves Dividend for the Fiscal Year 2020

Upcoming dividend of €1.34 per share

Fresenius Medical Care Confirms Earnings Guidance for the Fiscal Year 2021

First quarter 2021 earnings released: EPS €0.85 (vs €0.95 in 1Q 2020)

Fresenius Medical Care AG & Co. KGaA to Report Fiscal Year 2020 Final Results on Mar 23, 2021

Full year 2020 earnings released: EPS €3.96 (vs €3.96 in FY 2019)

Revenue misses expectations

Fresenius Medical Care AG & Co. KGaA to Report Q3, 2021 Results on Nov 02, 2021

Fresenius Medical Care's Frenova Enrolls Patients in Initiative to Build Large Genomic Registry Targeting Kidney Disease

Fresenius Medical Care AG & Co. KGaA, Annual General Meeting, May 20, 2021

Revenue misses expectations

Third quarter 2020 earnings released: EPS €1.21

Third quarter earnings released

Third-quarter earnings released: Revenue misses expectations

Fresenius Medical Care AG & Co. KGaA to Report Q1, 2020 Results on May 06, 2020

Rentabilidad de los accionistas

Volatilidad de los precios